Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in alzheimer's disease Tg2576 Mice

AAPS Journal

Volumn 15, Issue 2, 2013, Pages 324-336

  Cheng, Kwok Kin ^a   Yeung, Chin Fung ^a   Ho, Shuk Wai ^a   Chow, Shing Fung ^a   Chow, Albert H L ^a   Baum, Larry ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Alzheimer's disease; behavior tests; nanocurcumin; oral route; pharmacokinetic

Indexed keywords

BETA CYCLODEXTRIN; COPOLYMER; CURCUMIN; NANOPARTICLE; PLACEBO; POLYETHYLENE GLYCOL POLYLACTIC ACID COPOLYMER; POVIDONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; FEMALE; MALE; MEMORY CONSOLIDATION; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; WORKING MEMORY; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; ANIMALS; BEHAVIOR, ANIMAL; BETA-CYCLODEXTRINS; BLOOD-BRAIN BARRIER; BRAIN; CHEMISTRY, PHARMACEUTICAL; CONDITIONING (PSYCHOLOGY); CURCUMIN; DISEASE MODELS, ANIMAL; DOGS; DRUG STABILITY; FEAR; FEMALE; LACTATES; MADIN DARBY CANINE KIDNEY CELLS; MALE; MAZE LEARNING; MEMORY; MICE; MICE, TRANSGENIC; NANOPARTICLES; NANOTECHNOLOGY; NOOTROPIC AGENTS; PARTICLE SIZE; PERMEABILITY; PLAQUE, AMYLOID; POLYETHYLENE GLYCOLS; POVIDONE; TECHNOLOGY, PHARMACEUTICAL;

EID: 84877031136     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9444-4     Document Type: Article

References (59)

1. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement. 2012;8:131-68.
2. Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: A look to the future. Radiology. 2003;226:315-36.
3. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a non-specific imaging marker of amyloid-beta (Aβ) peptide-related cerebral amyloidosis. Brain. 2007;130:2607-15.
4. Reinke AA, Gestwicki JE. Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: Influence of linker length and flexibility. Chem Biol Drug Des. 2007;70:206-15.
5. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280:5892-901.
6. Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther. 2008;326:196-208.
7. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001;21:8370-7.
8. Cheng A, Hsu C, Lin J, Hsu M, Ho Y, Shen T, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21:2895-900.
9. Toennesen HH, Karlsen J. Studies on curcumin and curcuminoids. VI. Kinetics of curcumin degradation in aqueous solution. Z Lebensm Unters Forsch. 1985;180:402-4.
10. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharmaceutics. 2007;4:807-18.
11. Tønnesen HH, Másson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: Solubility, chemical and photochemical stability. Int J Pharm. 2002;244:127-35.
12. Liu A, Lou H, Zhao L, Fan P. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal. 2006;40:720-7.
13. Schranz JL. Coloring agents. Brit UK Pat Appl. 1984:5.
14. Todd PH, Jr. Curcumin complexed on water-dispersible substrates. United States Patent. 1991;US4999205.
15. Mathew A, Fukuda T, Nagaoka Y, Hasumura T, Morimoto H, Yoshida Y, et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PLoS One. 2012;7:e32616.
16. TM) in the neuronal cell culture and animal model: Implications for Alzheimer's disease. J Alzheimer's Dis. 2011;23:61-77.
17. Tsai Y, Chien C, Lin L, Tsai T. Curcumin and its nano-formulation: The kinetics of tissue distribution and blood-brain barrier penetration. Int J Pharm. 2011;416:331-8.
18. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol. 2010;79:330-8.
19. Gavi E, Rivautella L, Marchisio DL, Vanni M, Barresi AA, Baldi G. CFD modelling of nano-particle precipitation in confined impinging jet reactors. Chem Eng Res Design. 2007;85:735-44.
20. Gavi E, Marchisio DL, Barresi AA. CFD modelling and scale-up of confined impinging jet reactors. Chemical Engineering Science. 2007;62:2228-41.
21. Liu Y, Fox RO. CFD predictions for chemical processing in a confined impinging-jets reactor. AIChE J. 2006;52:731-44.
22. Liu Y, Cheng C, Liu Y, Prud'homme RK, Fox RO. Mixing in a multi-inlet vortex mixer (MIVM) for flash nano-precipitation. Chemical Engineering Science. 2008;63:2829-42.
23. Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD, et al. In vitro models for the blood-brain barrier. Toxicology in Vitro. 2005;19:299-334.
24. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev. 2004;36:57-104.
25. Zhang C, Kwan P, Zuo Z, Baum L. In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein. Life Sci. 2010;86:899-905.
26. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99-103.
27. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372-81.
28. Vickers AJ, Altman DG. Analysing controlled trials with baseline and follow up measurements. BMJ. 2001;323:1123-4.
29. Kakkar V, Singh S, Singla D, Kaur IP. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res. 2011;55:495-503.
30. Ghosh D, Choudhury ST, Ghosh S, Mandal AK, Sarkar S, Ghosh A, et al. Nanocapsulated curcumin: Oral chemopreventive formulation against diethylnitrosamine induced hepatocellular carcinoma in rat. Chem Biol Interact. 2012;195:206-14.
31. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MNVR. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009;37:223-30.
32. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A, et al. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): A novel strategy for human cancer therapy. Journal of Nanobiotechnology. 2007;5:3.
33. Couvreur P, Puisieux F. Nano- and microparticles for the delivery of polypeptides and proteins. Adv Drug Deliv Rev. 1993;10:141-62.
34. Yin Win K, Feng S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26:2713-22.
35. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: Effect of particle size. Pharm Res. 1996;13:1838-45.
36. Studart AR, Amstad E, Gauckler LJ. Colloidal stabilization of nanoparticles in concentrated suspensions. Langmuir. 2007;23:1081-90.
37. Gaucher G, Dufresne M, Sant VP, Kang N, Maysinger D, Leroux J. Block copolymer micelles: preparation, characterization and application in drug delivery. J Controlled Release. 2005;109:169-88.
38. Wang Q, Rager JD, Weinstein K, Kardos PS, Dobson GL, Li J, et al. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm. 2005;288:349-59.
39. Buckley ST, Fischer SM, Fricker G, Brandl M. In vitro models to evaluate the permeability of poorly soluble drug entities: Challenges and perspectives. Eur J Pharm Sci. 2012;45:235-50.
40. Quitschke W. Differential solubility of curcuminoids in serum and albumin solutions: Implications for analytical and therapeutic applications. BMC Biotechnol. 2008;8:84.
41. Shen L, Ji H. Contribution of degradation products to the anticancer activity of curcumin. Clin Cancer Res. 2009. doi: 10.1158/1078-0432.CCR-09-1749.
42. Pan M, Huang T, Lin J. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999;27:486-94.
43. Zhongfa L, Chiu M, Wang J, Chen W, Yen W, Fan-Havard P, et al. Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. Cancer Chemother Pharmacol. 2012;69:679-89.
44. Ireson CR, Jones DJL, Orr S, Coughtrie MWH, Boocock DJ, Williams ML, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev. 2002;11:105-11.
45. Rolls ET. A theory of hippocampal function in memory. Hippocampus. 1996;6:601-20.
46. Kim SJ, Son TG, Park HR, Park M, Kim M, Kim HS, et al. Curcumin stimulates proliferation of embryonic neural progenitor cells and neurogenesis in the adult hippocampus. J Biol Chem. 2008;283:14497-505.
47. Givens B, Olton D. Local modulation of basal forebrain: Effects on working and reference memory. J Neurosci. 1994;14:3578-87.
48. Stéphan A, Laroche S, Davis S. Generation of aggregated β-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J Neurosci. 2001;21:5703-14.
49. Liu IYC, Lyons WE, Mamounas LA, Thompson RF. Brain-derived neurotrophic factor plays a critical role in contextual fear conditioning. J Neurosci. 2004;24:7958-63.
50. Yao I, Takao K, Miyakawa T, Ito S, Setou M. Synaptic E3 ligase SCRAPPER in contextual fear conditioning: Extensive Behavioral phenotyping of Scrapper heterozygote and overexpressing mutant mice. PLoS One. 2011;6:e17317.
51. Curzon P, Rustay N, Browman K. Cued and contextual fear conditioning for rodents. In: Buccafusco J, Buccafusco J, editors. Methods of behavior analysis in neuroscience. Boca Raton, FL: CRC Press; 2009. Chapter 2.
52. Barnes P, Good M. Impaired Pavlovian cued fear conditioning in Tg2576 mice expressing a human mutant amyloid precursor protein gene. Behav Brain Res. 2005;157:107-17.
53. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, et al. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002;22:1858-67.
54. Dodart J, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. Immunization reverses memory deficits without reducing brain A[beta] burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452-7.
55. Ashe KH. Learning and memory in transgenic mice modeling Alzheimer's disease. Learn Mem. 2001;8:301-8.
56. Klein WL, Krafft GA, Finch CE. Targeting small Aβ oligomers: The solution to an Alzheimer's disease conundrum? Trends Neurosci. 2001;24:219-24.
57. Hsia AY, Masliah E, McConlogue L, Yu G, Tatsuno G, Hu K, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci. 1999;96:3228-33.
58. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature. 2006;440:352-7.
59. Ali RE, Rattan SIS. Curcumin's biphasic hormetic response on proteasome activity and heat-shock protein synthesis in human keratinocytes. Ann N Y Acad Sci. 2006;1067:394-9.